Showing 6971-6980 of 7740 results for "".
- Venus Concept Launches Venus Velocity for Laser Hair Removalhttps://practicaldermatology.com/news/venus-concept-launches-venus-velocity-for-laser-hair-removal/2458314/Venus Concept is bringing a new hair removal laser to the US. Venus Velocity is a diode laser for hair removal, permanent hair reduction, and the treatment of razor bumps. The device has two modes of operation (SLIDE and PULSE), three changeable s
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- NeoStrata Debuts Exuviance AGE REVERSE Hand Rejuvenatorhttps://practicaldermatology.com/news/neostrata-debuts-exuviance-age-reverse-hand-rejuvenator/2458321/NeoStrata Company, Inc. is rolling out Exuviance AGE REVERSE Hand Rejuvenator, an intensive two-step peel. This 10% Citric Acid Peel gently exfoliates rough patches, uncovering smooth skin and preparing hands for the Exuviance AGE REVERSE Hand R
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- La Roche-Posay Debuts New Prebiotic Skincare Linehttps://practicaldermatology.com/news/la-roche-posay-debuts-new-prebiotic-skincare-line/2458323/La Roche-Posay is rolling out a new prebiotic Skincare Line. TOLERIANE Double Repair Moisturizer comes in a full line of products, including an SPF version and two complementary cleansers. The skin's microbiome is comprised of more than 100 b
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of p
- La Roche-Posay Nabs 20 Beauty Awards in 2016https://practicaldermatology.com/news/la-roche-posay-nabs-20-beauty-awards-in-2016/2458336/La Roche-Posay (LRP) won 20 beauty awards, almost doubling its wins from the previous year, the company has announced. The awards, judged by editors, industry leaders and elite experts who test thousands of beauty products before awarding top honors, bring the total skincare wins for LRP to 55 an
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients